Giuseppe Viale Division of Pathology IEO, European Institute of Oncology IRCCS Biography Publications Institution JoVE Articles Giuseppe Viale has not added a biography. If you are Giuseppe Viale and would like to personalize this page please email our Author Liaison for assistance. Publications Comparison of HercepTest™ MAb PharmDx (Dako Omnis, GE001) with Ventana PATHWAY Anti-HER-2/neu (4B5) in Breast Cancer: Correlation with HER2 Amplification and HER2 Low Status Virchows Archiv : an International Journal of Pathology. Nov, 2022 | Pubmed ID: 35970977 Breast Cancer During Pregnancy As a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles Cells. Jul, 2022 | Pubmed ID: 35892583 Pathology After Neoadjuvant Treatment - How to Assess Residual Disease Breast (Edinburgh, Scotland). Mar, 2022 | Pubmed ID: 34810049 Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study Frontiers in Oncology. 2021 | Pubmed ID: 34504801 Economic Implications of ACOSOG Z0011 Trial Application into Clinical Practice at the European Institute of Oncology European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Oct, 2021 | Pubmed ID: 34172359 Heparanase: a Potential Marker of Worse Prognosis in Estrogen Receptor-positive Breast Cancer NPJ Breast Cancer. May, 2021 | Pubmed ID: 34050190 Intraoperative Irradiation for Early Breast Cancer (ELIOT): Long-term Recurrence and Survival Outcomes from a Single-centre, Randomised, Phase 3 Equivalence Trial The Lancet. Oncology. May, 2021 | Pubmed ID: 33845035 Patient-reported Function, Health-related Quality of Life, and Symptoms in APHINITY: Pertuzumab Plus Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer British Journal of Cancer. Jul, 2021 | Pubmed ID: 33828257 Gut Vascular Barrier Impairment Leads to Intestinal Bacteria Dissemination and Colorectal Cancer Metastasis to Liver Cancer Cell. May, 2021 | Pubmed ID: 33798472 Application of a Risk-management Framework for Integration of Stromal Tumor-infiltrating Lymphocytes in Clinical Trials NPJ Breast Cancer. 2020 | Pubmed ID: 32436923 DNA Methylation Markers Predict Recurrence-free Interval in Triple-negative Breast Cancer NPJ Breast Cancer. 2020 | Pubmed ID: 32025567 Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen As Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer JNCI Cancer Spectrum. Dec, 2019 | Pubmed ID: 32337480 Treatment Selection for Patients with Equivocal HER2 Status and in Luminal Versus HER2-enriched Disease Breast (Edinburgh, Scotland). Nov, 2019 | Pubmed ID: 31839160 Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy Cancers. Oct, 2019 | Pubmed ID: 31653094 Ki-67 (30-9) Scoring and Differentiation of Luminal A- and Luminal B-like Breast Cancer Subtypes Breast Cancer Research and Treatment. Nov, 2019 | Pubmed ID: 31422497 Clinical and Analytical Validation of Ki-67 in 9069 Patients from IBCSG VIII + IX, BIG1-98 and GeparTrio Trial: Systematic Modulation of Interobserver Variance in a Comprehensive in Silico Ring Trial Breast Cancer Research and Treatment. Aug, 2019 | Pubmed ID: 31065870 Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients Journal of Clinical Medicine. Jan, 2019 | Pubmed ID: 30669267 Immunohistochemical Versus Molecular (BluePrint and MammaPrint) Subtyping of Breast Carcinoma. Outcome Results from the EORTC 10041/BIG 3-04 MINDACT Trial Breast Cancer Research and Treatment. Jan, 2018 | Pubmed ID: 28929359 Controversies in Treatment Selection for Patients with Equivocal ER and HER2 Results Breast (Edinburgh, Scotland). Aug, 2017 | Pubmed ID: 28666922 HER2 Status Predicts for Upfront AI Benefit: A TRANS-AIOG Meta-analysis of 12,129 Patients From ATAC, BIG 1-98 and TEAM with Centrally Determined HER2 European Journal of Cancer (Oxford, England : 1990). Jul, 2017 | Pubmed ID: 28494403 Discordant Assessment of Tumor Biomarkers by Histopathological and Molecular Assays in the EORTC Randomized Controlled 10041/BIG 03-04 MINDACT Trial Breast Cancer : Intratumoral Heterogeneity and DCIS or Normal Tissue Components Are Unlikely to Be the Cause of Discordance Breast Cancer Research and Treatment. Feb, 2016 | Pubmed ID: 26820652 ESR1 and ESR2 Polymorphisms in the BIG 1-98 Trial Comparing Adjuvant Letrozole Versus Tamoxifen or Their Sequence for Early Breast Cancer Breast Cancer Research and Treatment. Dec, 2015 | Pubmed ID: 26590813 Predictive Value and Clinical Utility of Centrally Assessed ER, PgR, and Ki-67 to Select Adjuvant Endocrine Therapy for Premenopausal Women with Hormone Receptor-positive, HER2-negative Early Breast Cancer: TEXT and SOFT Trials Breast Cancer Research and Treatment. Nov, 2015 | Pubmed ID: 26493064 Negatively Charged AuNP Modified with Monoclonal Antibody Against Novel Tumor Antigen FAT1 for Tumor Targeting Journal of Experimental & Clinical Cancer Research : CR. Sep, 2015 | Pubmed ID: 26373379 A Bad Tumor Biomarker is As Bad As a Bad Drug: The Gap Between Genomics Data and Phenotype to Predict Response Breast (Edinburgh, Scotland). Nov, 2015 | Pubmed ID: 26255744 Molecular Analysis of Sentinel Lymph Nodes and Search for Molecular Signatures of the Metastatic Potential of Breast Cancer The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society Of.... Jun, 2014 | Pubmed ID: 24835292 High Concordance of Protein (by IHC), Gene (by FISH; HER2 Only), and Microarray Readout (by TargetPrint) of ER, PgR, and HER2: Results from the EORTC 10041/BIG 03-04 MINDACT Trial Annals of Oncology : Official Journal of the European Society for Medical Oncology. Apr, 2014 | Pubmed ID: 24667714 Characterization and Clinical Impact of Residual Disease After Neoadjuvant Chemotherapy Breast (Edinburgh, Scotland). Aug, 2013 | Pubmed ID: 24074800 Experts' Opinion: Recommendations for Retesting Breast Cancer Metastases for HER2 and Hormone Receptor Status Breast (Edinburgh, Scotland). Apr, 2013 | Pubmed ID: 23352656 The Current State of Breast Cancer Classification Annals of Oncology : Official Journal of the European Society for Medical Oncology. Sep, 2012 | Pubmed ID: 22987963 Pathological Work Up of the Primary Tumor: Getting the Proper Information out of It Breast (Edinburgh, Scotland). Oct, 2011 | Pubmed ID: 22015299 Which Patients Benefit Most from Adjuvant Aromatase Inhibitors? Results Using a Composite Measure of Prognostic Risk in the BIG 1-98 Randomized Trial Annals of Oncology : Official Journal of the European Society for Medical Oncology. Oct, 2011 | Pubmed ID: 21335417 What Can the Pathologist Offer for Optimal Treatment Choice? Annals of Oncology : Official Journal of the European Society for Medical Oncology. Oct, 2010 | Pubmed ID: 20943626 البنك الحيوي للطب الانتقالي: إجراءات التشغيل القياسية للإدارة المثلى للعينات Giuseppina Bonizzi*1, Maria Capra*1, Cristina Cassi1, Giulio Taliento1, Oriana Pala2, Elham Sajjadi2,3, Konstantinos Venetis2,3, Mariia Ivanova2, Massimo Monturano4, Giuseppe Renne2, Lorenzo Zattoni1,3, Elena Guerini-Rocco2,3, Giuseppe Viale2,3, Roberto Orecchia5, Nicola Fusco1,2,3 1Biobank for Translational and Digital Medicine Unit, IEO, European Institute of Oncology IRCCS, 2Division of Pathology, IEO, European Institute of Oncology IRCCS, 3Department of Oncology and Hemato-Oncology, University of Milan, 4Patient Safety & Risk Management Service, IEO, European Institute of Oncology IRCCS, 5Scientific Directorate, IEO, European Institute of Oncology IRCCS JoVE 63950 Cancer Research
البنك الحيوي للطب الانتقالي: إجراءات التشغيل القياسية للإدارة المثلى للعينات Giuseppina Bonizzi*1, Maria Capra*1, Cristina Cassi1, Giulio Taliento1, Oriana Pala2, Elham Sajjadi2,3, Konstantinos Venetis2,3, Mariia Ivanova2, Massimo Monturano4, Giuseppe Renne2, Lorenzo Zattoni1,3, Elena Guerini-Rocco2,3, Giuseppe Viale2,3, Roberto Orecchia5, Nicola Fusco1,2,3 1Biobank for Translational and Digital Medicine Unit, IEO, European Institute of Oncology IRCCS, 2Division of Pathology, IEO, European Institute of Oncology IRCCS, 3Department of Oncology and Hemato-Oncology, University of Milan, 4Patient Safety & Risk Management Service, IEO, European Institute of Oncology IRCCS, 5Scientific Directorate, IEO, European Institute of Oncology IRCCS JoVE 63950 Cancer Research